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Abstract 
A case of primary malignant melanoma of the urethra in a 60-year-old male is presented. 
Despite multiple adverse prognostic factors and against expectations, after a follow-up 
of 5.5 years he is still alive. 
 
Introduction 
Primary malignant melanoma of the urethra is rare, representing less than 1% of all 
melanomas [1, 2], which means that it is often misdiagnosed and treatment can be 
delayed. Given its poor prognosis, early diagnosis is essential, and clinicians need to 
include it in their differential diagnosis when working up a patient with genitourinary 
complaints. 
A working knowledge of the varied presentations associated with primary urethral 
melanoma as well as its histopathological features is an important component to early 
diagnosis and effective treatment. Many adverse prognostic factors exist such as age ≥60 
years, thickness ≥3.5 mm, ulceration and diameter ≥15 mm [3, 4]. However, the presence 
or absence of lymph node metastasis is the most significant prognostic factor for survival, 
as survival rates are approximately halved by the presence of nodal metastasis [2, 4]. 
Individual management according to the clinical presentation has to be based on 
extrapolation of evidence for other melanoma treatments. Due to the low occurrence of 
urethral melanoma, the optimum therapy has not been established in the urological field, 
and surgery remains the mainstay of primary therapy; adjuvant local-regional and 
systemic therapies are needed [5–7].  
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Case Report 
A 60-year-old man was admitted to our institution in March 2004 complaining of persistent urethral 
discharge and induration in the distal urethra.  
According to the patient’s history, there was a continuous urethral discharge, predominantly after 
sexual intercourse, known since September 2003. At that time he was empirically treated for prostatitis 
with Permixon (a compound lipid extract from the fruit of the American dwarf palm tree, Serenoa 
repens) and Nimesulid (non-steroidal anti-inflammatory drug). Subsequently, the patient was lost for 
follow-up. Anamnestically, he drank one liter of wine and smoked half a package of cigarettes per day. 
In March 2004, a smear-test of the urethra was negative and cystourethroscopy revealed red, slightly 
bleeding lesions in the distal urethra involving the colliculus seminalis. Antibiotic therapy (ciprofloxacin 
250 mg orally twice a day for 12 days) and biopsy were recommended, which were declined by the 
patient.  
Again he failed to attend follow-up appointments until 6 months later. At that time (in September 
2004), he was willing to undergo a transurethral biopsy because of increasing symptoms. 
Histopathological examination of the biopsy specimens revealed a solid, poorly differentiated neoplasia 
with large pleomorphic, fusiform and anaplastic cells, which were high-grade according to the WHO’s 
classification and highly suspicious for malignant melanoma. The diagnosis was supported by 
immunohistochemical staining with a marker for melanoma (anti-Vimentin+, ProteinS-100+, HMB-
45+, MelanA+; AE1/AE3+, CD20+). Atypical pigmented melanocytic cells were also noted in urinary 
cytologic samples. 
The metastatic workup, including physical examination, PET total body scan, total body CT-scan 
and bone scintigraphy showed palpable bilateral clinically pathological inguinal lymph nodes (2.5 × 
2 cm in diameter, round), with some lymph nodes in the mediastinum (pretracheal and near the 
bifurcation of the trachea) and bilateral axillae. 
In October 2004, a partial penectomy and urethrectomy (fig. 1) with negative surgical margins and a 
superficial inguinal lymph node dissection were performed. The final pathologic examination revealed a 
malignant ulcerated pigmented melanoma of the urethra with polyploidy solid pattern growth, 
intramucosal component and necrotic areas. Microscopically, it is formed of epitheloid, spindle, 
pleomorphic and anaplastic cells (MelanA+; HMB-45+; ProteinS-100+; Ki67/Mib1+ >20%) (fig. 2) 
infiltrating the subepithelial connective tissue and focally the corpus spongiosum. Areas of regression 
were not observed. Neoangiogenesis and vascular neoplastic invasion are present (CD34+), as bilateral 
metastatic disease in inguinal lymph nodes: pTMN sec WHO: pT2 N2 Mx Gx R0 V1 (Staging D sec. 
Levine [Cancer 1980]). 
A PET-scan revealed higher metabolic activity in the left inguinal region, and the patient was 
referred to a tertiary referral center for deep bilateral ilioinguinal, external iliac and obturator lymph 
node dissection in December 2004. One in 10 ilioinguinal lymph nodes showed metastatic disease 
involving the lymph node capsule, and 9 iliac and obturator lymph nodes showed reactive changes on 
the left side. On the right side, 13 ilioinguinal lymph nodes and 6 external iliac lymph nodes showed 
reactive changes. Postoperative complications included wound infection and chronic lymphedema, 
which were treated with antibiotics and lymph drainage therapy.  
A PET-scan in April 2005 showed a high activity in the liver, raising suspicion of hepatic metastatic 
disease in segment VIII. This was confirmed by ultrasonographic examination and CT-scan (diameter 
of 4.6 × 3.8 × 4.5 cm).  
Cystourethroscopy was performed in May 2005 because of a weak urinary stream and showed an 
urethral recurrence situated in the distal part of the urethra. The patient underwent distal urethral 
resection of the lesion, which was histologically a relapse of the primary melanoma that was confined to 
the mucosa.  
Subsequently, the patient underwent 6 cycles of carboplatin (CDDP 75 mg/m
2) and deticene (DTC 
800 mg/m
2), which were well tolerated. The CT-scan that was repeated in July 2005 showed a reduction 
in the diameter of the metastasis in the liver (1.3 cm vs. 4.6 cm in April), and it also showed a diffuse 
swelling of the dermis and subdermis in the inguinal region, which had not been visible at the previous 
CT. 
Until March 2006, repeated abdominal ultrasonographic examinations were performed with 
unchanged findings in the liver. In the additional follow-up in June 2006, cerebral metastases in the left  
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parietal lobe (3 lesions with a diameter of 3–10 mm) were found in the cerebral CT-scan and confirmed 
in the cerebral magnetic resonance imaging (MRI); the patient underwent chemotherapy with 
fotemustine (100 mg/m
2) every 3 weeks until May 2007.  
A control MRI in January 2007 showed a reduction in diameter of the cerebral metastasis. The 
CT-scan in October 2007 showed a reduction in diameter of the liver metastasis from 1.3 cm to 4 mm. 
Ultrasound of the abdomen in March 2009 presented a suspicious lesion in the pancreas that was not 
confirmed in an abdominal MRI.  
Since August 2009, the patient is just under conservative control. The patient is still alive (65 months 
after diagnosis) and is in good condition without signs of recurrence (follow-up by PET-CT in May 
2009). Fig. 3 shows his external genitalia in August 2009. 
Discussion 
Primary malignant melanomas of the genitourinary system are rare, representing less 
than 1% of all melanomas [1, 2]. Regarding urethral melanoma, mucosal sites are known 
to be associated with aggressive behavior, and from the onset of symptoms to the patient’s 
seeking medical care, there is often a considerable delay [8]. Therefore, biopsy of all 
pigmented urethral lesions is recommended [2]. 
The urethra, especially the distal urethra, including fossa navicularis and urethral 
meatus, is the most common location of melanomas of the urinary tract, and about 30% 
of patients already have metastasis at the time of diagnosis [7] and have reached 
dangerous limits (e.g., depth of invasion or thickness at the time of diagnosis) [9]. 
Adverse prognostic factors are known, such as thickness (significant cutoff ≥3.5 mm), 
ulceration and diameter (significant cutoff ≥15 mm) [3, 4]. 
Cancers of the anterior urethra preferentially drain into superficial inguinal lymph 
nodes. Those of the posterior urethra generally drain into pelvic lymphatic channels [7]. 
However, the presence or absence of lymph node metastasis is the most significant 
prognostic factor for survival, as survival rates are approximately halved by the presence 
of nodal metastasis [2, 4]. 
The prognosis of malignant melanoma of the urethra is poor (2-year-survival is about 
63% and 5-year-survival is 31% [3]) because of delayed diagnosis and treatment initiation.  
Because of the low occurrence of malignant melanoma in the urethra, no therapy has 
been established in the urologic field. Prevention of disease progression by surgery alone 
is not successful and requires effective postoperative adjuvant therapy [6, 10], such as 
lymph node dissection [2, 11], immunochemotherapy [12, 13] or adjuvant radiotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Case Rep Dermatol 2009;1:93–99 
DOI: 10.1159/000256663 
Published online: November 20, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
96
Table 1. Synopsis 
Date Symptoms    Investigation    Findings    Treatment 
09/2003 
(practitioner) 
Urethral discharge 
after sexual 
intercourse 
 Ultrasound 
Urine examination 
 Prostatitis   Antibiotic  therapy 
03/2004 
(in our  
institution) 
Urethral discharge 
Urethral induration 
 Cystourethroscopy 
Smear test (negative) 
  Slightly bleeding lesions in 
the distal urethra involving 
the colliculus seminalis 
 Recommended  biopsy 
and antibiotic therapy
09/2004 Urethral  discharge 
Urethral induration 
 Urethral  biopsy 
Cytology 
  Suspicious for malignant 
melanoma 
Atypical cells in cytologic 
samples 
 Recommended 
penectomy and 
urethrectomy 
09/2004      PET total body 
Total body CT-scan 
Bone scintigraphy 
 Bilateral  inguinal,  bilateral 
axillary and mediastinal 
lymph nodes 
  
10/2004     Partial  penectomy  and 
urethrectomy and 
superficial lymph node 
dissection 
  pT2 N2 Mx Gx R0 V1      
12/2004      Deep bilateral ilioinguinal 
lymph node, external iliac 
and obturator lymph 
nodes dissection 
  Left: 1/10 positive 
inguinocrural lymph nodes; 
9 iliac and obturator lymph 
nodes with reactive changes 
Right: 13 inguinocrural 
lymph nodes and 6 external 
iliac lymph nodes with 
reactive changes 
 Treatment  of  wound 
infection and chronic 
lymphedema 
04/2005     PET-scan 
Ultrasound 
CT-scan 
 Hepatic  metastatic  disease 
in segment VIII 
  
05/2005  Weak urinary stream   Cystourethroscopy  
Urethral biopsy and 
resection 
  Relapse of malignant 
melanoma in the urethra 
  
06/2005 None    Chemotherapy        Chemotherapy  with 
carboplatin (CDDP 75 
mg/m
2) and deticene 
(DTC 800 mg/m
2) 
6 cycles 
07/2005      CT-scan    Reduction of liver 
metastasis 
  
06/2006     Cerebral  CT-scan   
Cerebral MRI 
 Cerebral  metastasis    
Till 05/2007              Chemotherapy with 
fotemustine (100 
mg/m
2) every 3 weeks
01/2007      Cerebral MRI    Reduction of cerebral 
metastasis 
  
10/2007      CT-scan    Reduction of liver 
metastasis 
  
03/2009      Abdominal ultrasound    Suspicious lesion of the 
pancreas 
  
03/2009      MRI of the abdomen    Negative     
05/2009      PET-CT    No signs of recurrence     
08/2009  Patient in good 
general condition 
       Conservative 
treatment  
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Fig. 1. Longitudinal section of the penis and the urethra. 
 
 
 
Fig. 2. Urethral epithelium with a malignant intraepithelial melanoma, in situ component, and 
malignant melanoma with tumor mass; melanocytic tumor cells are evidenced with the antibody 
anti-MelanA. 
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Fig. 3. External genitalia after partial penectomy and urethrectomy. 
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